Takeda Cambridge

About Takeda Cambridge

Takeda Cambridge is the U.S. R&D headquarters for Takeda Pharmaceutical Company Limited, a global biopharmaceutical leader founded in 1781 by Chobei Takeda I in Osaka, Japan. The Cambridge, Massachusetts, campus is central to the company's global research and development efforts, unifying its R&D center with business operations in the Kendall Square life sciences hub. Takeda focuses its R&D on four core therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Genetics & Hematology. It also makes targeted investments in Plasma-Derived Therapies and Vaccines.

The company's business model integrates internal research with external innovation through its Center for External Innovation (CEI). This strategy involves strategic partnerships, venture investments, and acquisitions to build a diverse and robust pipeline. Takeda Ventures, its corporate venture capital arm founded in 2001, invests in early-stage companies with disruptive technologies that align with its R&D pillars. The company's R&D approach emphasizes four key modalities: small molecules, biologics, antibody-drug conjugates (ADCs), and allogeneic cell therapies. In 2020, Takeda opened a 24,000-square-foot R&D cell therapy manufacturing facility in Boston to advance its immuno-oncology pipeline and next-generation cell therapies.

Takeda generates revenue through the development and commercialization of its portfolio of medicines. Its U.S. presence is significant, with Cambridge being its global hub and the company ranking as the largest life sciences employer in Massachusetts. The company is consolidating its Cambridge presence into a single campus in Kendall Square, with a new 600,000-square-foot facility designed for modern R&D and flexible work. This site focuses on oncology, gastroenterology, biologics, and translational research. Takeda is guided by a philosophy called "Takeda-ism," which prioritizes integrity, fairness, honesty, and perseverance, and a patient-centric approach to business.